Long-term persistence of RBD+ memory B cells encoding neutralizing antibodies in SARS-CoV-2 infection
Type
Report, ResearchAuthor/s
Abayasingam, A.Balachandran, H.
Agapiou, D.
Hammoud, M.
Rodrigo, C.
Keoshkerian, E.
Li, H.
Brasher, N.A.
Christ, D.
Rouet, R.
Burnet, D.
Grubor-Bauk, B.
Rawlinson, W.
Turville, S.
Aggarwa,l A.
Stella, A.O.
Fichter, C.
Brilot, F.
Mina, M.
Post, J.J.
Hudson, B.
Gilroy, N.
Dwyer, D.
Sasson, S.C.
Tea, F.
Pilli, D.
Kelleher, A.
Tedla, N.
Lloyd, A.R.
Martinello, M.
Bull, R.A.
on Behalf of the COSIN Study Group
Abstract
Considerable concerns relating to the duration of protective immunity against severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) exist, with evidence of antibody titers declining rapidly after infection and reports of reinfection. Here, we monitor the antibody responses ...
See moreConsiderable concerns relating to the duration of protective immunity against severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) exist, with evidence of antibody titers declining rapidly after infection and reports of reinfection. Here, we monitor the antibody responses against SARS-CoV-2 receptor-binding domain (RBD) for up to 6 months after infection. While antibody titers are maintained, _13% of the cohort's neutralizing responses return to background. However, encouragingly, in a selected subset of 13 participants, 12 have detectable RBD-specific memory B cells and these generally are increasing out to 6 months. Furthermore, we are able to generate monoclonal antibodies with SARS-CoV-2 neutralizing capacity from these memory B cells. Overall, our study suggests that the loss of neutralizing antibodies in plasma may be countered by the maintenance of neutralizing capacity in the memory B cell repertoire.
See less
See moreConsiderable concerns relating to the duration of protective immunity against severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) exist, with evidence of antibody titers declining rapidly after infection and reports of reinfection. Here, we monitor the antibody responses against SARS-CoV-2 receptor-binding domain (RBD) for up to 6 months after infection. While antibody titers are maintained, _13% of the cohort's neutralizing responses return to background. However, encouragingly, in a selected subset of 13 participants, 12 have detectable RBD-specific memory B cells and these generally are increasing out to 6 months. Furthermore, we are able to generate monoclonal antibodies with SARS-CoV-2 neutralizing capacity from these memory B cells. Overall, our study suggests that the loss of neutralizing antibodies in plasma may be countered by the maintenance of neutralizing capacity in the memory B cell repertoire.
See less
Date
2021Funding information
Royal North Shore Hospital, RNSH Australian Government NSW Health Pathology National Health and Medical Research Council, NHMRC Department of Health and Ageing, Australian Government University of New South Wales, UNSW University of Sydney, Usyd Marie Bashir Institute, University of Sydney
Licence
OtherFaculty/School
Faculty of Medicine and Health, Sydney Medical SchoolShare